Q Therapeutics, Inc., a clinical-stage company committed to find new therapies that might address central nervous system (CNS) diseases, has recently announced that the United States Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug Application (IND) so that Q-Cells’ Phase 1/2a trials can be initiated in patients with amyotrophic lateral sclerosis (ALS). ALS,…
Q Therapeutics, Inc., a company focused on adult stem cell therapies for disorders of the central nervous system, recently announced that its product Q-Cells® has received Investigational New Drug (IND) clearance by the U.S. Food and Drug Administration (FDA) for the start of Phase 1/2a clinical trials in…
In a recent study published in the journal BMC Neurology researchers found that despite the lack of a curative therapy, Amyotrophic Lateral Sclerosis carergivers (including specialized physicians as well as nursing and familial caregivers) can substantially contribute to the maintenance of quality of life (QoL) at the…
In a new study entitled “Dietary Vitamin D3 Restriction Exacerbates Disease Pathophysiology in the Spinal Cord of the G93A Mouse Model of Amyotrophic Lateral Sclerosis,” researchers evaluated the effects of a Vitamin D dietary restriction in the pathogenesis of Amyotrophic lateral sclerosis. The study was performed with…
Dr. Erik P. Pioro at the Neurological Institute, Cleveland Clinic in Ohio conducted a review on clinical data supporting treatment with dextromethorphan (DM) hydrobromide combined with quinidine sulfate (Q) for a disorder called pseudobulbar affect (PBA) that can occur in amyotrophic lateral sclerosis (ALS) patients. The study was published…
The following are a series of Frequently Asked Questions (FAQ) pertaining to clinical trials, and what the process entails: What is a clinical trial? Clinical trials are well-designed studies that collect information about new treatments for diseases and disorders. Most of the time, this means medications, but clinical trials can…
A new study conducted by researchers at the Universidad Nacional Autónoma de México in Mexico recently revealed new insights into the mechanisms underlying motor neuron degeneration, offering potential new treatment strategies for amyotrophic lateral sclerosis (ALS). The study is entitled “Degeneration of spinal motor neurons by…
A new study led by researchers at the Mayo Clinic and recently published in the journal Science reported a new, important mouse model that allows the study of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia, two relevant neurodegenerative diseases. The study is entitled “…
French pharmaceutical company AB Science SA has organized a web conference to present information on its lead product for the treatment of amyotrophic lateral sclerosis (ALS), a drug therapy called masitinib. The seminar held by AB Science, which is specialized in developing and commercializing protein…
The Annual Drug Company Working Group and the American Academy of Neurology (AAN) meetings were recently held by the ALS Association last month in Washington, D.C. with main focus on amyotrophic lateral sclerosis (ALS). The association is now sharing the most important data presented at the…
